Podcast Description:
During this podcast, Dr. Rony Nehmé and Dr. Markus Seeger will discuss how they joined forces to shed light on Sybodies binding onto SARS-CoV-2 Spike RBD, after preselection from three large combinatorial libraries in just 12 days and kinetic
screening characterization using the GCI technology.
Learning Objectives:
- Off-rate screening as a tool to narrow down pools of synthetic nanobodies (sybodies)
- Rapid kinetic characterization of sybodies using the GCI technology
- Setting up and analyzing competition studies, binding kinetics
- Fast ELISA validation using the GCI technology to correlate data from competition assays
Dr. Rony Nehmé
Application Scientist, Creoptix AG
With over 10 years of experience in the membrane proteins field, Dr. Rony Nehmé has a deep and solid understanding of GPCRs biology, pharmacology and structural studies. He was an Investigator Scientist in the lab of Prof. Chris Tate (MRC-LMB in Cambridge) prior to joining Creoptix in 2018 as an Application Scientist. He holds a PhD in molecular biology from the Université de Nice-Sophia Antipolis in France.
Dr. Markus Seeger
Assistant Professor, Institute of Medical Microbiology, University of Zurich
Dr. Markus Seeger leads a research group investigting the engineering and selection of synthetic binders against membrane proteins of pathogenic bacteria. He holds an MSc in Biotechnology and a PhD in Microbiology from the ETH in Zurich. After a postdoctoral stay at the Univerity of Cambridge (UK), he became Junior Group Leader and later Assistant Professor at the University of Zurich in 2013. His groups designs synthetic nanobodies (sybodies) – raised in vitro as conformation-specific affinity reagents against membrane proteins.
Dr. André Heuer
Sales Development Manager, Creoptix AG